Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes.
about
Associations of sex hormone-binding globulin and testosterone with diabetes among men and women (the Saku Diabetes study): a case control studyTestosterone for the aging male; current evidence and recommended practiceThe benefits and risks of testosterone replacement therapy: a reviewClinically and pharmacologically relevant interactions of antidiabetic drugsThe treatment of late-onset hypogonadismMetabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trialsOutcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinologyAlzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactionsTestosterone and the cardiovascular system: a comprehensive review of the clinical literatureAndropause: Current conceptsInfluence of androgens on circulating adiponectin in male and female rodentsTestosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practicesEffects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studiesHormone replacement therapy and physical function in healthy older men. Time to talk hormones?Testosterone improves the differentiation efficiency of insulin-producing cells from human induced pluripotent stem cells.The effects of opioids and opioid analogs on animal and human endocrine systemsEffects on lipoprotein particles of long-term dehydroepiandrosterone in elderly men and women and testosterone in elderly men.Clinical significance of androgen secretion disorders in men with a malignancy.MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease.Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men.Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS).Glycemic control and prostate cancer progression: results from the SEARCH database.The role of the urologist in the prevention and early detection of cardiovascular disease.Testosterone and weight loss: the evidence.A practical guide to male hypogonadism in the primary care setting.An update on male hypogonadism therapy.Diet-induced obesity and low testosterone increase neuroinflammation and impair neural functionTestosterone deficiency associated with poor glycemic control in korean male diabetics.Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications.Influence of testosterone replacement therapy on metabolic disorders in male patients with type 2 diabetes mellitus and androgen deficiency.Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormonesLow testosterone concentration and atherosclerotic disease markers in male patients with type 2 diabetes.Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study).Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study.Men's health, low testosterone, and diabetes: individualized treatment and a multidisciplinary approach.Testosterone deficiency and cardiovascular mortality.Prediabetes is associated with an increased risk of testosterone deficiency, independent of obesity and metabolic syndrome.Sex-specific effects of high fat diet on indices of metabolic syndrome in 3xTg-AD mice: implications for Alzheimer's disease.Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetesTestosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine?
P2860
Q24633948-3DBFE952-6DD3-477D-A2AE-2ABE575559BCQ24647679-71FFB3EA-6E60-45AF-A418-83FAB0AC3016Q24658011-A527C17F-5009-419C-968E-E5D60D3F5A05Q26752468-4F7102BF-D387-4BCC-BAFF-25C74D1F9EFEQ26795519-9FCB68B3-3D2C-4629-BCBE-843DB51FB2C6Q26822761-69C6106E-EE0C-4285-912F-E64BEA32C2C3Q26864777-F8AA3183-5C91-4EA3-B2FF-0A39F901AC9FQ26864965-20665874-0EB3-4F3E-A2EF-B59D4683262BQ27000507-E6D1B6D0-3BEC-4CFB-A271-DD280FEDC3B7Q27024886-E9B75AFE-A841-44AC-99E0-DFC06C703327Q27314775-2C3EEAD0-CB13-4EF7-B1EF-18F3EDB3A952Q28295533-5A9B3637-951C-489C-BD07-369ED71E290DQ30983590-6AA86388-04EA-455F-971D-7C7A86DCEC8DQ33569163-3AFA3874-E1C2-4682-A562-6A0B65E6DDBFQ33778800-7028CF26-5924-40C1-8740-6847B06D9695Q33779667-91169117-1892-4A0A-B848-1FDFDA4D4D46Q33786842-1949CB29-6719-4CC6-A29A-A231E7C14001Q33840617-710EE2F9-C395-4D73-B3F4-2EA48347D41BQ33904576-18A496CE-E13A-4BAA-8A12-7A99547726E3Q33932837-109C96CB-E465-43BA-8BDA-3C8B40F973AEQ34063853-7CC6AB65-89D8-4EC4-B435-DFAA55ED472FQ34091905-F6F8770F-3A49-4FFE-8685-3A38BC538B4EQ34108216-A34C1773-088F-4E9D-AB70-9D8B58B4E418Q34134273-0B31F934-FD0F-4E2A-A143-9A0CE875CBEAQ34167760-8E8153B8-F02B-4B32-ABAA-23276421A80AQ34207540-560E9EDA-5D75-435C-BED0-8BF3849B022EQ34309465-B8F3AB96-E6B7-4CD2-9203-DEC5EBCF72C0Q34318818-CECF4002-4103-47AF-A868-7A5ACDF52D20Q34398768-F416094F-1EC4-48D3-BED0-17553CD0A0CFQ34422927-67A8416E-7769-4DC4-9DF3-BF019BE1BF57Q34590954-8656437C-6C82-455A-B1FA-E9924144D5D2Q34628361-A6ABDC92-7D78-44CF-A804-2459EAC90730Q34718357-1B6D0332-F33B-42F3-9D48-6A9071C8FC65Q34804834-F993A696-E1F2-4770-B235-7B720967DF2FQ34884322-FE8C6953-1EE0-4487-9A62-61C72EE45A43Q34927884-BFBDFF22-0B4C-46DE-BFF6-9B3BEAD24940Q34999016-17880359-5D53-42E2-ABB0-6D58D3DA3A80Q35036518-2B0A0BDD-1796-47A8-81CA-7EBAEC42DB04Q35060256-D6E9CF33-12EB-43BD-B183-D27ECD3BD3A7Q35076387-47BF4772-5588-4BBE-B51A-C995C66D93E1
P2860
Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Testosterone replacement thera ...... adal men with type 2 diabetes.
@ast
Testosterone replacement thera ...... adal men with type 2 diabetes.
@en
Testosterone replacement thera ...... adal men with type 2 diabetes.
@nl
type
label
Testosterone replacement thera ...... adal men with type 2 diabetes.
@ast
Testosterone replacement thera ...... adal men with type 2 diabetes.
@en
Testosterone replacement thera ...... adal men with type 2 diabetes.
@nl
prefLabel
Testosterone replacement thera ...... adal men with type 2 diabetes.
@ast
Testosterone replacement thera ...... adal men with type 2 diabetes.
@en
Testosterone replacement thera ...... adal men with type 2 diabetes.
@nl
P2093
P921
P356
P1476
Testosterone replacement thera ...... adal men with type 2 diabetes.
@en
P2093
P304
P356
10.1530/EJE.1.02166
P577
2006-06-01T00:00:00Z